Facilities and environment

World-class manufacturing environment (cGMP compliant)

Our facilities are fully compliant with the pharmaceutical manufacturing and quality control standards (cGMP), and we conduct process verification based on “Quality by Design,” which incorporates quality from the design stage. This ensures consistent high quality and safety.

Data integrity

Manufacturing records and quality data are strictly managed using an electronic document management system compliant with 21 CFR Part 11. We ensure data reliability and transparency and are prepared for future web audits. We provide peace of mind to our customers.

Rapid support from domestic locations

With manufacturing facilities located in Japan, we enable seamless communication and swift responses without time zone differences. We promptly address customer requests and provide robust support for research and development.

High-purity cleanroom (ISO Class 7 / Grade C)

We minimize particulate and microbial contamination in an ISO Class 7-compliant cleanroom suitable for RNA synthesis. We manufacture stable, high-purity RNA products.

Aseptic filling system (ISO Class 5 isolator)

Filling processes are conducted in an isolator system that boasts the highest level of sterile environment (ISO Class 5/Grade A). We provide safe products under strict sterile management.

Enhanced quality control system (GLP-compliant analysis)

We are progressively introducing GLP-compliant analytical equipment and establishing various test items. By leveraging the latest analytical technologies, we aim to establish a more precise quality evaluation and improvement cycle.

ItemSpecifications / Details
Manufacturing history documentscGMP compliant
Manufacturing environmentmRNA manufacturing: ISO Class 7
Aseptic filling: ISO Class 5
Raw material managementTraceable, supplier management
Manufacturing scale100 mg to 50 g

Quality Contorol

QualityAttributeMethodPreclinicalcGMP Compliant
IdentitySequence ConfirmationSanger Sequencing
ContentRNA QuantificationUV Absorbance
IntegritymRNA IntegrityCapillary Gel Electrophoresis (CGE)
PurityPurity ConfirmationRP-HPLC
5’ Capping EfficiencyLC-MS
3’ poly(A) Tail LengthLC-MS
Impurities originating from the productdsRNAELISA
AggregatesSEC-HPLC
Short Fragment Insertion RateRP-HPLC
Residual DNA TemplateqPCR
Residual NucleotidesLC-MS
Residual ReagentsAnion exchange-HPLC
Residual T7 PolymeraseELISA
PotencyProtein ExpressionCellular transfection and evaluation
SafetyEndotoxin TestUSP <85>、JP<4.01>
Microbial Limit TestUSP <61>, <62>, <1115>
JP<4.05>
OtherVisual InspectionUSP <790>
Residual SolventUSP <467>、JP<2.46>
pHUSP <791>、JP<2.54>

Ref. : Analytical Procedures for Quality of mRNA Vaccines and Therapeutics (Draft Guidelines: 3rd Edition)

*Please contact us if you would like additional quality control and evaluation.